Given that they were the two most up-regulated genes in the CD79B-mutated DLBCL group in our study, further investigations are needed to determine whether they are involved in CD79B-mutated DLBCL development either separately or via a (HIF-1α)-ARNT2-mediated WNT11 activation and whether this feature can be used as a new therapeutic target in this lymphoma group. This evidence concerns the gene CD79B and lymphoma.